• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CKD 患者接受饮食蛋白质限制后,肠道微生物群及其相关代谢物的组成和功能适应性变化。

Compositional and Functional Adaptations of Intestinal Microbiota and Related Metabolites in CKD Patients Receiving Dietary Protein Restriction.

机构信息

Department of Nephrology, Chang Gung Memorial Hospital, Keelung 20401, Taiwan.

College of Medicine, Chang Gung University, Taoyuan 33305, Taiwan.

出版信息

Nutrients. 2020 Sep 12;12(9):2799. doi: 10.3390/nu12092799.

DOI:10.3390/nu12092799
PMID:32932711
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7551076/
Abstract

The relationship between change of gut microbiota and host serum metabolomics associated with low protein diet (LPD) has been unraveled incompletely in CKD patients. Fecal 16S rRNA gene sequencing and serum metabolomics profiling were performed. We reported significant changes in the β-diversity of gut microbiota in CKD patients having LPD (CKD-LPD, = 16). We identified 19 genera and 12 species with significant differences in their relative abundance among CKD-LPD patients compared to patients receiving normal protein diet (CKD-NPD, = 27) or non-CKD controls ( = 34), respectively. CKD-LPD had a significant decrease in the abundance of many butyrate-producing bacteria (family and ) associated with enrichment of functional module of butanoate metabolism, leading to concomitant reduction in serum levels of SCFA (acetic, heptanoic and nonanoic acid). A secondary bile acid, glyco λ-muricholic acid, was significantly increased in CKD-LPD patients. Serum levels of indoxyl sulfate and p-cresyl sulfate did not differ among groups. The relationship between abundances of microbes and metabolites remained significant in subset of resampling subjects of comparable characteristics. Enrichment of bacterial gene markers related to D-alanine, ketone bodies and glutathione metabolism was noted in CKD-LPD patients. Our analyses reveal signatures and functions of gut microbiota to adapt dietary protein restriction in renal patients.

摘要

在慢性肾脏病(CKD)患者中,尚未完全阐明肠道微生物群的变化与低蛋白饮食(LPD)相关的宿主血清代谢组学之间的关系。进行了粪便 16S rRNA 基因测序和血清代谢组学分析。我们报告了 LPD 患者肠道微生物群β多样性的显著变化(CKD-LPD,n=16)。与接受正常蛋白饮食(CKD-NPD,n=27)或非 CKD 对照(n=34)的患者相比,我们分别在 CKD-LPD 患者中鉴定出 19 个属和 12 个种的相对丰度存在显著差异。与丁酸盐代谢功能模块的富集相关,CKD-LPD 患者中许多产生丁酸盐的细菌(科和科)的丰度显著降低,导致血清 SCFA(乙酸、庚酸和壬酸)水平降低。次级胆汁酸甘氨胆酸的水平在 CKD-LPD 患者中显著增加。各组之间的吲哚硫酸酯和对甲酚硫酸酯的血清水平没有差异。在具有相似特征的重采样亚组中,微生物和代谢物丰度之间的关系仍然显著。在 CKD-LPD 患者中注意到与 D-丙氨酸、酮体和谷胱甘肽代谢相关的细菌基因标志物的富集。我们的分析揭示了肠道微生物群适应肾脏患者饮食蛋白限制的特征和功能。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8815/7551076/5569938fb81e/nutrients-12-02799-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8815/7551076/8d308e4acec8/nutrients-12-02799-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8815/7551076/108a6462336c/nutrients-12-02799-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8815/7551076/5569938fb81e/nutrients-12-02799-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8815/7551076/8d308e4acec8/nutrients-12-02799-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8815/7551076/108a6462336c/nutrients-12-02799-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8815/7551076/5569938fb81e/nutrients-12-02799-g003.jpg

相似文献

1
Compositional and Functional Adaptations of Intestinal Microbiota and Related Metabolites in CKD Patients Receiving Dietary Protein Restriction.CKD 患者接受饮食蛋白质限制后,肠道微生物群及其相关代谢物的组成和功能适应性变化。
Nutrients. 2020 Sep 12;12(9):2799. doi: 10.3390/nu12092799.
2
Does Low-Protein Diet Influence the Uremic Toxin Serum Levels From the Gut Microbiota in Nondialysis Chronic Kidney Disease Patients?低蛋白饮食是否会影响非透析慢性肾脏病患者肠道微生物群产生的尿毒症毒素血清水平?
J Ren Nutr. 2018 May;28(3):208-214. doi: 10.1053/j.jrn.2017.11.007. Epub 2018 Feb 10.
3
Effect of Low-Protein Diet and Inulin on Microbiota and Clinical Parameters in Patients with Chronic Kidney Disease.低蛋白饮食和菊粉对慢性肾脏病患者肠道菌群和临床参数的影响。
Nutrients. 2019 Dec 9;11(12):3006. doi: 10.3390/nu11123006.
4
Integrative metagenomic and metabolomic analyses reveal severity-specific signatures of gut microbiota in chronic kidney disease.整合宏基因组学和代谢组学分析揭示慢性肾脏病严重程度特异性的肠道微生物组特征。
Theranostics. 2020 Apr 6;10(12):5398-5411. doi: 10.7150/thno.41725. eCollection 2020.
5
Effects of Low Protein Diet on Modulating Gut Microbiota in Patients with Chronic Kidney Disease: A Systematic Review and Meta-analysis of International Studies.低蛋白饮食对慢性肾脏病患者肠道微生物群调节作用的国际研究系统评价和荟萃分析。
Int J Med Sci. 2021 Oct 25;18(16):3839-3850. doi: 10.7150/ijms.66451. eCollection 2021.
6
Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS-based metabolomics approach.基于 CE-TOFMS 的代谢组学方法评价肠道微生物群对尿毒症溶质积累的影响。
Kidney Int. 2017 Sep;92(3):634-645. doi: 10.1016/j.kint.2017.02.011. Epub 2017 Apr 8.
7
Disorder of gut amino acids metabolism during CKD progression is related with gut microbiota dysbiosis and metagenome change.在 CKD 进展过程中,肠道氨基酸代谢紊乱与肠道微生物失调和宏基因组变化有关。
J Pharm Biomed Anal. 2018 Feb 5;149:425-435. doi: 10.1016/j.jpba.2017.11.040. Epub 2017 Nov 15.
8
Gut Microbiota as Diagnostic Tools for Mirroring Disease Progression and Circulating Nephrotoxin Levels in Chronic Kidney Disease: Discovery and Validation Study.肠道微生物群作为反映慢性肾脏病疾病进展和循环肾毒素水平的诊断工具:发现与验证研究
Int J Biol Sci. 2020 Jan 1;16(3):420-434. doi: 10.7150/ijbs.37421. eCollection 2020.
9
Integrated gut microbiota and fecal metabolomics reveal the renoprotective effect of Rehmanniae Radix Preparata and Corni Fructus on adenine-induced CKD rats.整合肠道微生物群和粪便代谢组学揭示熟地黄和山茱萸对腺嘌呤诱导的 CKD 大鼠的肾保护作用。
J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Jun 1;1174:122728. doi: 10.1016/j.jchromb.2021.122728. Epub 2021 Apr 24.
10
Alterations to the Gut Microbiota and Their Correlation With Inflammatory Factors in Chronic Kidney Disease.肠道微生物群的改变及其与慢性肾脏病中炎症因子的相关性。
Front Cell Infect Microbiol. 2019 Jun 12;9:206. doi: 10.3389/fcimb.2019.00206. eCollection 2019.

引用本文的文献

1
Gut Microbiome-Derived Short-Chain Fatty Acids in Glomerular Protection and Modulation of Chronic Kidney Disease Progression.肠道微生物群衍生的短链脂肪酸在肾小球保护及慢性肾脏病进展调控中的作用
Nutrients. 2025 Sep 8;17(17):2904. doi: 10.3390/nu17172904.
2
Gut Microbiome as a Risk Factor for Future CKD.肠道微生物群作为未来慢性肾脏病的一个风险因素。
Kidney Int Rep. 2025 Apr 7;10(6):1673-1682. doi: 10.1016/j.ekir.2025.04.007. eCollection 2025 Jun.
3
Multi-omics analysis reveals the efficacy of two probiotic strains in managing feline chronic kidney disease through gut microbiome and host metabolome.

本文引用的文献

1
Integrative metagenomic and metabolomic analyses reveal severity-specific signatures of gut microbiota in chronic kidney disease.整合宏基因组学和代谢组学分析揭示慢性肾脏病严重程度特异性的肠道微生物组特征。
Theranostics. 2020 Apr 6;10(12):5398-5411. doi: 10.7150/thno.41725. eCollection 2020.
2
Gut microbiota generation of protein-bound uremic toxins and related metabolites is not altered at different stages of chronic kidney disease.在慢性肾脏病的不同阶段,肠道微生物群产生蛋白质结合型尿毒症毒素及相关代谢产物的情况并未改变。
Kidney Int. 2020 Jun;97(6):1230-1242. doi: 10.1016/j.kint.2020.01.028. Epub 2020 Feb 17.
3
Gut Microbiota as Diagnostic Tools for Mirroring Disease Progression and Circulating Nephrotoxin Levels in Chronic Kidney Disease: Discovery and Validation Study.
多组学分析揭示了两种益生菌菌株通过肠道微生物群和宿主代谢组来管理猫慢性肾病的功效。
Front Vet Sci. 2025 Jun 18;12:1590388. doi: 10.3389/fvets.2025.1590388. eCollection 2025.
4
Kidney-Gut Axis in Chronic Kidney Disease: Therapeutic Perspectives from Microbiota Modulation and Nutrition.慢性肾脏病中的肾-肠轴:微生物群调节与营养的治疗前景
Nutrients. 2025 Jun 9;17(12):1961. doi: 10.3390/nu17121961.
5
Machine-learning assisted discovery unveils novel interplay between gut microbiota and host metabolic disturbance in diabetic kidney disease.机器学习辅助发现揭示了糖尿病肾病中肠道微生物群与宿主代谢紊乱之间的新型相互作用。
Gut Microbes. 2025 Dec;17(1):2473506. doi: 10.1080/19490976.2025.2473506. Epub 2025 Mar 6.
6
The potential mediating role of the gut microbiome and metabolites in the association between PFAS and kidney function in young adults: A proof-of-concept study.肠道微生物组和代谢物在全氟和多氟烷基物质与年轻人肾功能之间的关联中的潜在中介作用:概念验证研究。
Sci Total Environ. 2024 Dec 1;954:176519. doi: 10.1016/j.scitotenv.2024.176519. Epub 2024 Oct 17.
7
Alterations of the gut microbiota and metabolites by ShenZhu TiaoPi granule alleviates hyperglycemia in GK rats.参术调脾颗粒对肠道微生物群和代谢物的改变可减轻GK大鼠的高血糖。
Front Microbiol. 2024 Aug 29;15:1420103. doi: 10.3389/fmicb.2024.1420103. eCollection 2024.
8
The compositional and functional imbalance of the gut microbiota in CKD linked to disease patterns.慢性肾脏病中与疾病模式相关的肠道微生物菌群组成和功能失衡。
J Transl Med. 2024 Aug 16;22(1):773. doi: 10.1186/s12967-024-05578-w.
9
Blood Microbiota and Its Products: Mechanisms of Interference with Host Cells and Clinical Outcomes.血液微生物群及其产物:干扰宿主细胞的机制与临床结局
Hematol Rep. 2024 Jul 6;16(3):440-453. doi: 10.3390/hematolrep16030043.
10
Liquid Chromatography-Mass Spectrometry Analytical Methods for the Quantitation of -Cresol Sulfate and Indoxyl Sulfate in Human Matrices: Biological Applications and Diagnostic Potentials.液相色谱-质谱联用法定量分析人体基质中对甲酚硫酸盐和吲哚酚硫酸盐的分析方法:生物学应用及诊断潜力
Pharmaceutics. 2024 May 30;16(6):743. doi: 10.3390/pharmaceutics16060743.
肠道微生物群作为反映慢性肾脏病疾病进展和循环肾毒素水平的诊断工具:发现与验证研究
Int J Biol Sci. 2020 Jan 1;16(3):420-434. doi: 10.7150/ijbs.37421. eCollection 2020.
4
Effect of Low-Protein Diet and Inulin on Microbiota and Clinical Parameters in Patients with Chronic Kidney Disease.低蛋白饮食和菊粉对慢性肾脏病患者肠道菌群和临床参数的影响。
Nutrients. 2019 Dec 9;11(12):3006. doi: 10.3390/nu11123006.
5
Keto microbiota: A powerful contributor to host disease recovery.酮体微生物群:宿主疾病恢复的有力贡献者。
Rev Endocr Metab Disord. 2019 Dec;20(4):415-425. doi: 10.1007/s11154-019-09518-8.
6
Diversification of host bile acids by members of the gut microbiota.肠道微生物群成员对宿主胆汁酸的多样化作用。
Gut Microbes. 2020;11(2):158-171. doi: 10.1080/19490976.2019.1674124. Epub 2019 Oct 9.
7
Nutritional Therapy Modulates Intestinal Microbiota and Reduces Serum Levels of Total and Free Indoxyl Sulfate and P-Cresyl Sulfate in Chronic Kidney Disease (Medika Study).营养疗法调节慢性肾脏病患者的肠道微生物群并降低血清总硫酸吲哚酚和游离硫酸吲哚酚以及对甲酚硫酸酯水平(Medika研究)。
J Clin Med. 2019 Sep 10;8(9):1424. doi: 10.3390/jcm8091424.
8
Quantitative reduction in short-chain fatty acids, especially butyrate, contributes to the progression of chronic kidney disease.短链脂肪酸(尤其是丁酸盐)的定量减少会导致慢性肾脏病的进展。
Clin Sci (Lond). 2019 Sep 10;133(17):1857-1870. doi: 10.1042/CS20190171. Print 2019 Sep 13.
9
Targeted metabolomics study of serum bile acid profile in patients with end-stage renal disease undergoing hemodialysis.接受血液透析的终末期肾病患者血清胆汁酸谱的靶向代谢组学研究
PeerJ. 2019 Jun 17;7:e7145. doi: 10.7717/peerj.7145. eCollection 2019.
10
Microbiome-metabolomics reveals gut microbiota associated with glycine-conjugated metabolites and polyamine metabolism in chronic kidney disease.微生物组-代谢组学揭示了与慢性肾脏病中甘氨酸缀合代谢物和多胺代谢相关的肠道微生物群。
Cell Mol Life Sci. 2019 Dec;76(24):4961-4978. doi: 10.1007/s00018-019-03155-9. Epub 2019 May 30.